- Home
- KROS vs ORIC Comparison
KROS vs ORIC Comparison
Compare KROS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ORIC
- Stock Information
- Founded
- KROS 2015
- ORIC 2014
- Country
- KROS United States
- ORIC United States
- Employees
- KROS N/A
- ORIC N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- ORIC Health Care
- Exchange
- KROS Nasdaq
- ORIC Nasdaq
- Market Cap
- KROS 558.9M
- ORIC 362.9M
- IPO Year
- KROS 2020
- ORIC 2020
- Fundamental
- Price
- KROS $14.17
- ORIC $10.71
- Analyst Decision
- KROS Buy
- ORIC Strong Buy
- Analyst Count
- KROS 13
- ORIC 9
- Target Price
- KROS $20.63
- ORIC $18.29
- AVG Volume (30 Days)
- KROS 601.6K
- ORIC 987.5K
- Earning Date
- KROS 08-06-2025
- ORIC 08-11-2025
- Dividend Yield
- KROS N/A
- ORIC N/A
- EPS Growth
- KROS N/A
- ORIC N/A
- EPS
- KROS 0.11
- ORIC N/A
- Revenue
- KROS $214,713,000.00
- ORIC N/A
- Revenue This Year
- KROS $5,006.76
- ORIC N/A
- Revenue Next Year
- KROS N/A
- ORIC N/A
- P/E Ratio
- KROS $127.57
- ORIC N/A
- Revenue Growth
- KROS 91657.70
- ORIC N/A
- 52 Week Low
- KROS $9.12
- ORIC $3.90
- 52 Week High
- KROS $72.37
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- KROS 59.31
- ORIC 67.12
- Support Level
- KROS $13.26
- ORIC $10.42
- Resistance Level
- KROS $13.77
- ORIC $11.14
- Average True Range (ATR)
- KROS 0.37
- ORIC 0.59
- MACD
- KROS 0.05
- ORIC -0.08
- Stochastic Oscillator
- KROS 92.54
- ORIC 79.49
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.